HONG KONG – The Korean Ministry of Food and Drug Safety (MFDS) is shortening the biologics review process for rare and incurable diseases to speed up the approvals and overseas distribution of Korea-developed biopharmaceuticals. Although details of the policy are sketchy and yet to be disclosed, the announcement marks the country’s determination to make biopharmaceuticals a core industry.
HONG KONG – With the successful completion of a phase II study in the U.S. for its flagship product, VM202, for the treatment of critical limb ischemia (CLI), South Korean biopharma Viromed Co. Ltd. is off to a good start this year.
HONG KONG – South Korea's Samsung Bioepis Co. Ltd. got the first EU approval for biosimilar etanercept, a win that opens up the European market for a company that is working to become a global top-tier biosimilar maker.
HONG KONG – South Korea's Samsung Bioepis Co. Ltd. got the first EU approval for biosimilar etanercept, a win that opens up the European market for a company that is working to become a global top-tier biosimilar maker.
HONG KONG – Samsung Biologics broke ground this week on its third and largest biopharmaceutical production plant. Once completed, the company expects the KRW850 billion (US$722 million) plant in Incheon, Korea, to be the largest in the world.
HONG KONG – Samsung Biologics broke ground Monday on its third and largest biopharmaceutical production plant. Once completed, the company expects the KRW850 billion (US$722 million) plant in Incheon, Korea, to be the largest in the world.
HONG KONG – Marking another step forward for South Korea's leading biosimilar developer, the Ministry of Food and Drug Safety (MFDS) approved domestic sales of Samsung Bioepis Co. Ltd.'s Renflexis (infliximab), a biosimilar of Johnson & Johnson's Remicade (infliximab). This is the second marketing approval for the company this year.
